A Multi-center, Randomized, Double-blind, Active Controlled, Parallel Groups, Phase II Study to Evaluate the Efficacy and Safety of HRS-8427 in the Treatment of Adults With Hospital-acquired Bacterial Pneumonia (HABP) or Ventilator-associated Bacterial Pneumonia (VABP)
Latest Information Update: 06 May 2025
At a glance
- Drugs HRS 8427 (Primary) ; Meropenem
- Indications Nosocomial pneumonia; Ventilator associated pneumonia
- Focus Therapeutic Use
- Sponsors Jiangsu Hengrui Medicine Co.
Most Recent Events
- 22 Apr 2025 Status changed from not yet recruiting to recruiting.
- 26 Feb 2025 New trial record